FDA bestows 'breakthrough' on AbbVie hep C combo, Scioderm 'fragile skin' therapy
This article was originally published in Scrip
Executive Summary
As more companies are granted the FDA's breakthrough therapy designation, which is aimed at speeding the development and review processes for medicines intended to treat serious or life-threatening diseases, investor excitement over the status appears to be waning.